Paper41512959
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum.
Lacombe D and 18 others. J Cancer Policy, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum. Papers, record 41512959. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41512959
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Quality of Life | |
| European Union |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 001 | World Health Organization | International | PubMed |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38779087 | EORTC 2238 "De-Escalate": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors. | Front Oncol | 2024 | https://conductscience.org/library/papers/38779087 | PubMed |
| 2 | 40553420 | Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD. | Target Oncol | 2025 | https://conductscience.org/library/papers/40553420 | PubMed |
| 3 | 32936713 | Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/32936713 | PubMed |
| 4 | 29565196 | Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development. | Curr Med Res Opin | 2018 | https://conductscience.org/library/papers/29565196 | PubMed |
| 5 | 38081195 | The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology. | Lancet | 2024 | https://conductscience.org/library/papers/38081195 | PubMed |
| 6 | 35205637 | Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35205637 | PubMed |
| 7 | 33746750 | What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33746750 | PubMed |
| 8 | 33764385 | Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/33764385 | PubMed |
| 9 | 30999145 | Establishing treatment optimisation as part of personalised medicine development. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/30999145 | PubMed |
| 10 | 38263138 | Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-Pragmatic Research and Innovation through Multinational Experimentation. | Trials | 2024 | https://conductscience.org/library/papers/38263138 | PubMed |
| 11 | 36400101 | European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/36400101 | PubMed |
| 12 | 40318657 | Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer. | Lancet Oncol | 2025 | https://conductscience.org/library/papers/40318657 | PubMed |
| 13 | 38492274 | Elements of successful patient involvement in clinical cancer trials: a review of the literature. | ESMO Open | 2024 | https://conductscience.org/library/papers/38492274 | PubMed |
| 14 | 32116718 | Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32116718 | PubMed |
| 15 | 28987771 | 'Mind the gap' between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research. | Eur J Cancer | 2017 | https://conductscience.org/library/papers/28987771 | PubMed |
| 16 | 27595308 | Publicly funded practice-oriented clinical trials: of importance for healthcare payers. | J Comp Eff Res | 2016 | https://conductscience.org/library/papers/27595308 | PubMed |
| 17 | 36109818 | Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases. | Trials | 2022 | https://conductscience.org/library/papers/36109818 | PubMed |
| 18 | 39844438 | Experiences with low-intervention clinical trials-the new category under the European Union Clinical Trials Regulation. | Clin Trials | 2025 | https://conductscience.org/library/papers/39844438 | PubMed |
| 19 | 39271845 | Post-approval evidence generation: a shared responsibility for healthcare. | Nat Med | 2024 | https://conductscience.org/library/papers/39271845 | PubMed |
| 20 | 34623789 | The Drug-Dosing Conundrum in Oncology - When Less Is More. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34623789 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41512959
GET https://conductscience.org/api/papers/v1/41512959/references?page=2